CTIS2024-514934-19-00进行中（未招募）1 期
An interventional, Phase III, double-blind, randomized, controlled, parallel-group, multi-site, clinical trial evaluating the efficacy and safety of Qutenza® in subjects with post-surgical neuropathic pain - AV001
Averitas Pharma Inc.0 个研究点目标入组 407 人开始时间: 2024年7月15日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 407
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •The subject has given written informed consent to participate., The subject experiencing pain is: a. currently not receiving treatment for PSNP or b. receives a stable systemic treatment for PSNP that started more than 30 days prior to the Randomization Visit (Visit 2)., Female or male subjects aged 18 years or older., For women of childbearing potential: negative pregnancy tests at Screening Visit (Visit 1), the Randomization Visit (Visit 2), and prior to each reapplication of the IMP, and must have agreed to practice medically acceptable methods of birth control., Documented diagnosis of PSNP by the following criteria: a. A history of post-surgical pain with a duration of at least 6 months to maximally 60 months that is plausibly related to the surgical intervention as documented on a body map. b. DN4i of at least 3 out of 7 points at Visit 1. c. The pain must extend beyond the scar area to neuroanatomically adjacent skin areas and be related to the site of the surgery., Documented diagnosis of probable or definite PSNP according to the following criteria: a. The pain must be associated with sensory signs in the same neuroanatomically plausible distribution. The area of sensory changes may extend beyond, be within, or overlap with the area of pain (criterion for probable neuropathic pain), or b. In addition to 5a: Direct surgical evidence (e.g., surgeon´s clear verification of an intraoperative nerve lesion) (criterion for definite neuropathic pain)., The subject has moderate to severe pain with a baseline value for 24- hr average pain intensity of at least 4 points on the NPRS. The baseline value is calculated as the average of the 24-hr average pain intensity ratings of the Baseline Phase (Day -7 to Day -1). At least 5 (out of the last 7 days) pain ratings should be available during the Baseline Phase. If less than 5 pain ratings are available in the last 7 days, the subject may be rescheduled for Visit 2 (1 time only) after having received appropriate re-training in the use of the e-diary to ensure compliance., The size of the affected painful intact skin area is not larger than the size of 4 standard Qutenza topical systems (1120 cm2)., The skin in the area where the IMP will be applied, and that may also contain the scar tissue, is intact, dry, and non-irritated (i.e., there are no signs and symptoms of skin disease, skin irritation, inflammation or injury, such as active herpes zoster lesions, atopic dermatitis, ulceration, wounds). This is reflected by a dermal assessment score of 0 = no evidence of irritation or 1 = minimal erythema, barely perceptible., The subject is willing to adhere to the restricted use of concomitant treatments (see concomitant treatments in Section 1.4.2).
排除标准
- •The subject received Qutenza before the Randomization Visit (Visit 2) or received a medical device in another clinical trial within 7 days before the Randomization Visit (Visit 2), or a. Any former use of topical capsaicin in the area of the PSNP before Visit 2, except for the use of a low-dose (<1%) capsaicin product – but not within 7 days before Visit 2. b. The subject participated previously in this clinical trial or participated in another clinical trial for the treatment of PSNP completing less than 3 months ago., The subject has a history of alcohol or drug abuse or is actively abusing drugs (including alcohol, medication) during the 1 year prior to the Screening Visit (Visit 1) as judged by the investigator., Evidence or history of severe psychiatric illness/disorder during the 3 years prior to the Screening Visit (Visit 1) that, in the investigator's opinion, may affect efficacy or safety assessments or may compromise the subject's safety during trial participation, e.g., major depression, major anxiety disorder, psychosis, severe personality disorders., Evidence of cognitive impairment including dementia that may interfere with the subject's ability to complete pain assessments requiring recall of the average pain level in the past 24 hrs., Surgical intervention in the last 3 months preceding the Screening Visit (Visit 1) if it is affecting the efficacy or safety assessments, or any scheduled or planned surgery during the trial, with the exception of the Extension Phase if the planned surgery is not expected to affect the efficacy or safety assessments., Patients with current clinically significant disease(s) or condition(s) (including clinically significant cardiovascular disease and/or significant pain in other areas) that may affect efficacy or safety assessments, or any other reason which, in the investigator's opinion, may preclude the subject's participation in the full duration of the trial. Patients with current signs and symptoms consistent with Coronavirus disease 2019 (COVID-19) (e.g., dry cough, dyspnea, sore throat, fatigue, fever) or subjects who had those symptoms within the last 14 days prior to screening and had a positive SARS-CoV2 PCR test result., Unstable or poorly controlled blood pressure which, in the opinion of the investigator, would put the subject at risk of severe adverse blood pressure increases upon IMP application., Known or suspected of not being able to comply with the requirements of the trial protocol or the instructions of the trial site staff., Not able to communicate meaningfully with the trial site staff., The subject is an employee of the investigator or trial site, with direct involvement in the proposed trial or other trials under the direction of that investigator or trial site, or is a family member of the employees or the investigator., A score of 0 out of 5 in all 3 categories of the neurological/sensory examinations, i.e., for warm sensation, pinprick and cold sensation at the Screening Visit (Visit 1)., The subject reported a 24-hr average pain intensity score of 10 on the NPRS for at least 4 days during the Baseline Phase., Any painful procedure planned during the course of the trial that may, in the opinion of the investigator, affect the efficacy or safety assessments., Subjects with PSNP related to a surgery/condition with a high potential for confounding symptoms, e.g., the pain is at least partially due to pain in deeper structures such as muscles or bones (including ref
研究者
相似试验
进行中（未招募）
1 期
A multi site clinical trial to evaluate the efficacy and safety of Qutenza® in subjects with post-surgical neuropathic paiPost-surgical neuropathic pain (PSNP)MedDRA version: 21.0Level: LLTClassification code 10054095Term: Neuropathic painSystem Organ Class: 100000004852EUCTR2021-001409-64-ESAveritas Pharma, Inc.510
招募中
3 期
An interventional, Phase III, double-blind, randomized, controlled, parallel-group, multi-site, clinical trial evaluating the efficacy and safety of Qutenza® in subjects with post-surgical neuropathic paiNL-OMON55934Averitas Pharma, Inc.49
进行中（未招募）
1 期
A multi site clinical trial to evaluate the efficacy and safety of Qutenza® in subjects with post-surgical neuropathic paiPost-surgical neuropathic pain (PSNP)MedDRA version: 21.0Level: LLTClassification code 10054095Term: Neuropathic painSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-001409-64-PLAveritas Pharma, Inc.510
进行中（未招募）
1 期
A multi site clinical trial to evaluate the efficacy and safety of Qutenza® in subjects with post-surgical neuropathic paiPost-surgical neuropathic pain (PSNP)MedDRA version: 21.0Level: LLTClassification code 10054095Term: Neuropathic painSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-001409-64-NLAveritas Pharma, Inc.510
已完成
不适用
PsA-TT-007Nervous System DiseasesPaediatricsMeningitisPACTR201110000328305Serum Institute of India Ltd (SIIL)1,500